Rapport Therapeutics, Inc. (RAPP) stock
RAPPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$26.15+0.30 (+1.16%)
Close on Nov 13, 2026Market cap $1.25BP/E –Yield –
Rapport Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Rapport Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $148.70M, up 81.9% year over year. For fiscal 2025 it was $94.79M, up 55.6% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $94.79M | +55.6% |
| FY2024 | Dec 31, 2024 | $60.94M | +117.6% |
| FY2023 | Dec 31, 2023 | $28.00M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $34.32M | +54.0% |
| Q2 FY2026 | Jun 30, 2026 | $51.41M | +126.7% |
| Q1 FY2026 | Mar 31, 2026 | $32.72M | +67.2% |
| Q4 FY2025 | Dec 31, 2025 | $30.26M | +75.9% |
| Q3 FY2025 | Sep 30, 2025 | $22.28M | +43.3% |
| Q2 FY2025 | Jun 30, 2025 | $22.68M | +44.6% |
| Q1 FY2025 | Mar 31, 2025 | $19.57M | +56.5% |
| Q4 FY2024 | Dec 31, 2024 | $17.20M | +45.8% |
| Q3 FY2024 | Sep 30, 2024 | $15.54M | +105.1% |
| Q2 FY2024 | Jun 30, 2024 | $15.69M | +232.3% |
| Q1 FY2024 | Mar 31, 2024 | $12.50M | – |
| Q4 FY2023 | Dec 31, 2023 | $11.80M | – |
| Q3 FY2023 | Sep 30, 2023 | $7.58M | – |
| Q2 FY2023 | Jun 30, 2023 | $4.72M | – |
See a number that looks wrong?